441330-00-3

Basic information

• Product Name: (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)-CARBAMIC ACID TERT-BUTYL ESTER
• CAS NO: 441330-00-3
• Molecular Formula: C15H23N3O2
• Molecular Weight: 277.36202
• Mol File: 441330-00-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)-CARBAMIC ACID TERT-BUTYL ESTER(441330-00-3)
• EPA Substance Registry System: (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)-CARBAMIC ACID TERT-BUTYL ESTER(441330-00-3)

Safety Data

• Hazardous Substances Data: 441330-00-3(Hazardous Substances Data)

Upstream product

• 626-61-9 4-Chloropyridine 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 144465-94-1 4-amino-1-(pyridin-2-yl)piperidine 
• 187084-44-2 3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylamine 

Relevant articles and documents

Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand

A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described. Structural requirements for P4 ligands in combination with a neutral biaryl P1 ligand were investigated with the 2-carboxyindole scaffold. A diverse set of P4 substituents was identified, which, in conjunction with a biaryl P1 ligand, gave highly potent factor Xa inhibitors, which were also selective versus other proteases and efficacious in various antithrombotic secondary assays.

Pyrazole-derivatives as factor Xa inhibitors

The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Inhibitors of factor Xa

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

New indole derivatives as factor Xa inhibitors

The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.

Inhibitors of factor Xa

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.